For Customers: From the JMCC Global Sales Team
The coronavirus has been wreaking havoc on a global medical cannabis industry already undergoing restructuring and major transition as well as expanding markets as more countries legalize cannabis for medical purposes and as research expands.
During these unsettled times, we want you to know that JMCC’s Global Sales Team is here to work with and support our customers to overcome obstacles you may be facing. Whether it's a minor change in delivery schedules or unique packaging requirements or even special delivery needs, we want to help, if possible. Please reach out to contact me at firstname.lastname@example.org at any time.
Here is an update on where we are in various parts of the world:
In Canada, we are currently working with several Licensed Producer customers to obtain permits from Health Canada for initial (R&D) imports. As our contracts stipulate, this is a prerequisite for commercial imports of JMCC medical cannabis product to Canada.
In Australia, we’ve signed Letters of Intent with various customers with full commercial licenses that allow them to import medical cannabis for the growing number of patients under the country’s special access schemes.
In Europe, where EU-GMP certification is generally required for imported medical cannabis, our customers are just waiting for us to achieve certification and we’re on our way!
In the United Kingdom, please see the news release about JMCC’s participation in Project Twenty21.
In Jamaica, due to delays in finalizing export regulations, most recently because of the pandemic, the Cannabis Licensing Authority has issued “interim measures” to facilitate exports. It’s expected they will issue final regulations this summer.